Diabetes, Neuro And Pain Franchises Propel Medtronic To A Strong Finish
Executive Summary
Medtech's number one player Medtronic reported solid fourth-quarter results, beating market analysts' forecasts and wrapping up a strong fiscal year 2018. Star performers in the final quarter were its diabetes and restorative therapies businesses.
You may also be interested in...
ADA2018: Medtronic Touts Power of Artificial Intelligence, New Pediatric Indication, Payer Guarantee Program
Medtronic created a lot of news at this year's annual American Diabetes Association conference in Orlando, Fla. The medtech giant officially launched the Guardian Connect with Sugar.IQ app to help diabetics better manage their care; announced the pediatric expansion for the MiniMed 670G hybrid closed loop system along with real-world data; and just days later, announced a new payer guarantee program. At ADA2018, Medtech Insight caught up with Medtronic's VP of Connected Care and its chief medical officer to learn about the latest developments at the company, and future plans.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.